{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:11:33Z","timestamp":1774991493130,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20260101029JJ"],"award-info":[{"award-number":["20260101029JJ"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571509"],"award-info":[{"award-number":["32571509"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32500685"],"award-info":[{"award-number":["32500685"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470831"],"award-info":[{"award-number":["32470831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most tumors exhibit increased glucose uptake and reprogram metabolism to aerobic glycolysis to meet their demands for macromolecule biosynthesis and energy production. Consequently, PET\/CT using 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG-PET\/CT) has been developed and is clinically utilized in cancer imaging diagnostics. However, numerous cancers demonstrate negative imaging during 18F-FDG-PET\/CT detection, suggesting these cancers employ alternative metabolic rewiring. In this study, we discovered that 18F-FDG-PET\/CT-negative gastric cancers coordinate glutamine-based gluconeogenesis and fatty acid oxidation to meet DNA and ATP demands, sustaining tumor growth despite low glucose uptake. PCK and CPT1A, the key enzymes which are responsible for remodeling the metabolism, were highly expressed in FDG-PET\/CT-negative gastric cancers. Accordingly, PCK\/CPT1A negatively correlated with 18F-FDG imaging levels and positively correlated with poorer clinical classifications. Mechanistically, PPAR\u03b3 is highly expressed in FDG-PET\/CT-negative cells and drives the transcription of the PCK and genes. Pharmacological inhibition of the PCK\/CPT1A significantly suppressed tumor growth in 18F-FDG-PET\/CT-negative gastric cancers, as demonstrated in both cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models. Together, these results highlight the heterogeneity of tumor cells from metabolic perspective, and identify PCK\/CPT1A as a target for metabolic reprogramming and precision therapy of 18F-FDG-PET\/CT-negative cancers.<\/jats:p>","DOI":"10.1038\/s41419-026-08662-9","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:28:04Z","timestamp":1774524484000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["18F-FDG-PET\/CT-negative gastric cancer employs glutamine-based gluconeogenesis and fatty acid oxidation to support tumor growth"],"prefix":"10.1038","volume":"17","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhexuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunxin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9945-6961","authenticated-orcid":false,"given":"Min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0198-9434","authenticated-orcid":false,"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"8662_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrc2981","volume":"11","author":"RA Cairns","year":"2011","unstructured":"Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85\u201395.","journal-title":"Nat Rev Cancer"},{"key":"8662_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441\u201364.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"8662_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.","journal-title":"Sci Adv"},{"key":"8662_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27\u201347.","journal-title":"Cell Metab"},{"key":"8662_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"8662_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrc3038","volume":"11","author":"WH Koppenol","year":"2011","unstructured":"Koppenol WH, Bounds PL, Dang CV. Otto Warburg\u2019s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325\u201337.","journal-title":"Nat Rev Cancer"},{"key":"8662_CR7","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/09553002.2019.1589653","volume":"95","author":"P Vaupel","year":"2019","unstructured":"Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95:912\u20139.","journal-title":"Int J Radiat Biol"},{"key":"8662_CR8","first-page":"1706","volume":"40","author":"D Delbeke","year":"1999","unstructured":"Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med. 1999;40:1706\u2013115.","journal-title":"J Nucl Med"},{"key":"8662_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s001170050556","volume":"39","author":"K Kletter","year":"1999","unstructured":"Kletter K, Becherer A. [FDG-PET in oncology. Methodological principles and clinical applications]. Radiologe. 1999;39:600\u20139.","journal-title":"Radiologe"},{"key":"8662_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s000660050022","volume":"175","author":"WA Weber","year":"1999","unstructured":"Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol. 1999;175:356\u201373.","journal-title":"Strahlenther Onkol"},{"issue":"Suppl 4","key":"8662_CR11","doi-asserted-by":"publisher","first-page":"iv23","DOI":"10.1136\/gut.52.suppl_4.iv23","volume":"52","author":"BB Chin","year":"2003","unstructured":"Chin BB, Wahl RL. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut. 2003;52(Suppl 4):iv23\u201329.","journal-title":"Gut"},{"key":"8662_CR12","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/sj.bjc.6604330","volume":"98","author":"F Castell","year":"2008","unstructured":"Castell F, Cook GJ. Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer. 2008;98:1597\u2013601.","journal-title":"Br J Cancer"},{"key":"8662_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"8662_CR14","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8662_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/bcr725","volume":"5","author":"JE Mortimer","year":"2003","unstructured":"Mortimer JE, Taylor ME. Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy. Breast Cancer Res. 2003;5:329\u201331.","journal-title":"Breast Cancer Res"},{"key":"8662_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5230\/jgc.2014.14.1.1","volume":"14","author":"M Yun","year":"2014","unstructured":"Yun M. Imaging of gastric cancer metabolism using 18 F-FDG PET\/CT. J Gastric Cancer. 2014;14:1\u20136.","journal-title":"J Gastric Cancer"},{"key":"8662_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11604-014-0294-0","volume":"32","author":"R Minamimoto","year":"2014","unstructured":"Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T, Inoue T. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer: results from a nationwide Japanese survey. Jpn J Radiol. 2014;32:253\u20139.","journal-title":"Jpn J Radiol"},{"key":"8662_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10120-018-0847-5","volume":"22","author":"HJ Chon","year":"2019","unstructured":"Chon HJ, Kim C, Cho A, Kim YM, Jang SJ, Kim BO, et al. The clinical implications of FDG-PET\/CT differ according to histology in advanced gastric cancer. Gastric Cancer. 2019;22:113\u201322.","journal-title":"Gastric Cancer"},{"key":"8662_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"8662_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/metabo9120282","volume":"9","author":"F Rajas","year":"2019","unstructured":"Rajas F, Gautier-Stein A, Mithieux G. Glucose-6 phosphate, A central hub for liver carbohydrate metabolism. Metabolites. 2019;9:282.","journal-title":"Metabolites"},{"key":"8662_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1152\/physrev.1992.72.2.419","volume":"72","author":"RL Jungas","year":"1992","unstructured":"Jungas RL, Halperin ML, Brosnan JT. Quantitative analysis of amino acid oxidation and related gluconeogenesis in humans. Physiol Rev. 1992;72:419\u201348.","journal-title":"Physiol Rev"},{"key":"8662_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbcan.2019.05.006","volume":"1872","author":"G Grasmann","year":"2019","unstructured":"Grasmann G, Smolle E, Olschewski H, Leithner K. Gluconeogenesis in cancer cells - Repurposing of a starvation-induced metabolic pathway. Biochim Biophys Acta Rev Cancer. 2019;1872:24\u201336.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8662_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.trecan.2018.11.003","volume":"5","author":"Z Wang","year":"2019","unstructured":"Wang Z, Dong C. Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase. Trends Cancer. 2019;5:30\u201345.","journal-title":"Trends Cancer"},{"key":"8662_CR24","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.3390\/ijms19124109","volume":"19","author":"HL Waldum","year":"2018","unstructured":"Waldum HL, Fossmark R. Types of gastric carcinomas. Int J Mol Sci. 2018;19:4109.","journal-title":"Int J Mol Sci"},{"key":"8662_CR25","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.celrep.2019.04.052","volume":"27","author":"P Zhang","year":"2019","unstructured":"Zhang P, Yang M, Zhang Y, Xiao S, Lai X, Tan A, et al. Dissecting the single-cell transcriptome network underlying gastric premalignant lesions and early gastric cancer. Cell Rep. 2019;27:1934\u20131947.e5.","journal-title":"Cell Rep"},{"key":"8662_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0022-5347(05)65845-4","volume":"166","author":"S Ramdave","year":"2001","unstructured":"Ramdave S, Thomas GW, Berlangieri SU, Bolton DM, Davis I, Danguy HT, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2001;166:825\u201330.","journal-title":"J Urol"},{"key":"8662_CR27","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.21037\/qims-22-1420","volume":"13","author":"Y Yao","year":"2023","unstructured":"Yao Y, Civelek AC, Li XF. The application of (18)F-FDG PET\/CT imaging for human hepatocellular carcinoma: a narrative review. Quant Imaging Med Surg. 2023;13:6268\u201379.","journal-title":"Quant Imaging Med Surg"},{"key":"8662_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/35093131","volume":"413","author":"S Herzig","year":"2001","unstructured":"Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413:179\u201383.","journal-title":"Nature"},{"key":"8662_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nature01667","volume":"423","author":"P Puigserver","year":"2003","unstructured":"Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423:550\u20135.","journal-title":"Nature"},{"key":"8662_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tem.2005.03.010","volume":"16","author":"A Barthel","year":"2005","unstructured":"Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab. 2005;16:183\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"8662_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","volume":"79","author":"P Tontonoz","year":"1994","unstructured":"Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147\u201356.","journal-title":"Cell"},{"key":"8662_CR32","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1101\/gad.10.9.1096","volume":"10","author":"JB Kim","year":"1996","unstructured":"Kim JB, Spiegelman BM. ADD1\/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996;10:1096\u2013107.","journal-title":"Genes Dev"},{"key":"8662_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/35093050","volume":"413","author":"JC Yoon","year":"2001","unstructured":"Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413:131\u20138.","journal-title":"Nature"},{"key":"8662_CR34","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/MCB.20.5.1868-1876.2000","volume":"20","author":"RB Vega","year":"2000","unstructured":"Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000;20:1868\u201376.","journal-title":"Mol Cell Biol"},{"key":"8662_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-nutr-080508-141134","volume":"29","author":"SF Previs","year":"2009","unstructured":"Previs SF, Brunengraber DZ, Brunengraber H. Is there glucose production outside of the liver and kidney. Annu Rev Nutr. 2009;29:43\u201357.","journal-title":"Annu Rev Nutr"},{"key":"8662_CR36","doi-asserted-by":"publisher","first-page":"14419","DOI":"10.1074\/jbc.REV120.012758","volume":"295","author":"AM Shah","year":"2020","unstructured":"Shah AM, Wondisford FE. Tracking the carbons supplying gluconeogenesis. J Biol Chem. 2020;295:14419\u201329.","journal-title":"J Biol Chem"},{"key":"8662_CR37","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.7150\/thno.58655","volume":"11","author":"A Mukha","year":"2021","unstructured":"Mukha A, Kahya U, Linge A, Chen O, L\u00f6ck S, Lukiyanchuk V, et al. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics. 2021;11:7844\u201368.","journal-title":"Theranostics"},{"key":"8662_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41588-020-00753-3","volume":"53","author":"AK Najumudeen","year":"2021","unstructured":"Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53:16\u201326.","journal-title":"Nat Genet"},{"key":"8662_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.medj.2022.08.005","volume":"3","author":"J Sponagel","year":"2022","unstructured":"Sponagel J, Jones JK, Frankfater C, Zhang S, Tung O, Cho K, et al. Sex differences in brain tumor glutamine metabolism reveal sex-specific vulnerabilities to treatment. Med. 2022;3:792\u2013811.e12.","journal-title":"Med"},{"key":"8662_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112899","volume":"42","author":"M Kodama","year":"2023","unstructured":"Kodama M, Toyokawa G, Sugahara O, Sugiyama S, Haratake N, Yamada Y, et al. Modulation of host glutamine anabolism enhances the sensitivity of small cell lung cancer to chemotherapy. Cell Rep. 2023;42:112899.","journal-title":"Cell Rep"},{"key":"8662_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s43018-023-00647-3","volume":"5","author":"J Encarnaci\u00f3n-Rosado","year":"2024","unstructured":"Encarnaci\u00f3n-Rosado J, Sohn A, Biancur DE, Lin EY, Osorio-Vasquez V, Rodrick T, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nat Cancer. 2024;5:85\u201399.","journal-title":"Nat Cancer"},{"key":"8662_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/onc.2009.358","volume":"29","author":"RJ DeBerardinis","year":"2010","unstructured":"DeBerardinis RJ, Cheng T. Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29:313\u201324.","journal-title":"Oncogene"},{"key":"8662_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1471-4159.2003.01981.x","volume":"87","author":"JW Deitmer","year":"2003","unstructured":"Deitmer JW, Br\u00f6er A, Br\u00f6er S. Glutamine efflux from astrocytes is mediated by multiple pathways. J Neurochem. 2003;87:127\u201335.","journal-title":"J Neurochem"},{"key":"8662_CR44","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.bbamcr.2015.12.017","volume":"1863","author":"YD Bhutia","year":"2016","unstructured":"Bhutia YD, Ganapathy V. Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta. 2016;1863:2531\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"8662_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-030-65768-0_2","volume":"1311","author":"T Li","year":"2021","unstructured":"Li T, Copeland C, Le A. Glutamine metabolism in cancer. Adv Exp Med Biol. 2021;1311:17\u201338.","journal-title":"Adv Exp Med Biol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08662-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08662-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:01:57Z","timestamp":1774987317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08662-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8662"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08662-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}